Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,150 Cr
Low Risk
86.5
32.3
1.2
4.6
475.55
400.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Sai Parenterals Ltd (SAIPARENT) is currently trading at 486.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sai Parenterals Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Sai Parenterals Ltd has traded between a low of ₹400.00 and a high of ₹475.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sai Parenterals Ltd has a market capitalization of approximately 2,150.20. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sai Parenterals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 86.55 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,150.20 Cr, Sai Parenterals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sai Parenterals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sai Parenterals Ltd is 86.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
As of the morning of the third and final day, the Sai Parenteral IPO was subscribed 43%. The Non-Institutional Investors (NII) portion was oversubscribed at 1.08 times, while the retail (RII) and QIB portions were subscribed 7% and 60%, respectively.
The IPO opens for public subscription on March 24, 2026, and closes on March 27, 2026. The allotment of shares is expected on March 30, and the listing is scheduled for April 2, 2026.
Bearish
1
Neutral
13
Bullish
0
Bearish
3
Neutral
37
Bullish
6
Bearish
2
Neutral
24
Bullish
6
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
994.40 | 2,433 Cr | 25.24 | 3.14 | 2.54 | 13.75 | 17.93 | 10.43 | ||
37.98 | 2,356 Cr | 21.10 | 1.97 | 0.47 | 6.31 | 8.14 | 5.77 | ||
183.10 | 2,336 Cr | -172.74 | 1.96 | 0.42 | 0.85 | 4.28 | -0.55 | ||
358.30 | 2,226 Cr | -298.58 | 2.69 | 0.00 | -5.71 | -5.58 | -0.65 | ||
469.95 | 2,150 Cr | 86.55 | 4.58 | 0.00 | 0.00 | 0.00 | 0.00 | ||
196.45 | 1,982 Cr | -15.59 | 2.02 | 0.09 | -11.28 | -2.11 | -4.64 | ||
771.55 | 1,862 Cr | 24.61 | 3.49 | 0.65 | 12.60 | 16.43 | 8.20 | ||
| Median: 7 Co. | — | 358.30 | 2,226 Cr | 21.10 | 2.69 | 0.42 | 0.85 | 4.28 | 0.00 |
Subsidiary loan
Board approved provision of unsecured loan up to AUD 1.75 million (SGD 1.61 million; INR 11,91,40,000) to wholly‑owned Sai Singapore Pte. Ltd. for downstream investment in step‑down subsidiary Noumed Pharmaceuticals Pty Ltd (Australia).
Subsidiary Loan Approval
Board approved an unsecured loan up to AUD 1.75M (SGD 1.61M; ~INR 11.91 crore) to wholly‑owned Sai Singapore Pte. Ltd. for downstream funding to step‑down subsidiary Noumed Pharmaceuticals Pty Ltd (Australia).
